clinical trial · NCT06140836
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Bristol-Myers Squibb·phase3·active not recruiting·n = 190
Carcinoma, Non-Small-Cell LungRepotrectinibCrizotinib
brief summary
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
started
Dec 21, 2023
primary completion
Mar 13, 2026
completion
Mar 15, 2027
last updated
Nov 21, 2025
official title
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol